Department of Medicine

Division of Hematology and Oncology

Christopher R. Cogle, M.D. Division Hematology/Oncology Assistant Professor of Medicine 1600 SW Archer Road /Box 100278 Gainesville, FL 32610-0278 (352) 273-7493 / FAX (352) 392-8530

Dr. Christopher R. Cogle is a physician-scientist with clinical and research expertise in the myelodysplastic syndromes, acute leukemias, and bone marrow failure syndromes. Dr. Cogle uses blood & marrow transplantation as a treatment option for patients who need more than chemotherapy to eradicate disease. Dr. Cogle also runs a stem cell research laboratory where he dissects the mechanisms of bone marrow-derived blood vessels. His research has made significant impact in the fields of cancer and cardiology. Dr. Cogle’s overall goal is to design safer and more effective methods of treating diseases by tapping into the potential of hematopoietic stem and progenitor cells.

Training:

Professional Summary:

http://www.cogle.com/

Academic Interests:

Dr. Cogle’s research focus is on human hematopoietic stem cells and cancer initiating cells. Specifically, his laboratory is focused on the following projects:

Defining the Hemangioblast Activity of the Human Hematopoietic Stem Cell (HSC)
This project aims to define the ability of the human hematopoietic stem cell in repairing injured blood vessels. To test this hypothesis we track blood vessel repair in immunocompromised mice transplanted with human HSC enriched from umbilical cord blood, bone marrow and mobilized peripheral blood. Additionally, we study new blood vessel growth in patients and try to determine to what extent the bone marrow is the origin.

Defining the Pathologic Hemangioblast Activity of the Hematopoietic Stem Cell in Cancer Blood Vessel Development
This project seeks to define the ability of the hematopoietic stem cell and bone marrow in contributing to the pathologic growth of blood vessels within cancer. To test this hypothesis we analyze blood vessels growing within cancers asking to what extent they are of bone marrow origin. We have developed anti-cancer treatments based on this research.

Bone Marrow Cell Injections for Heart Disease
This project tests the ability of bone marrow cells to repair hearts after heart attacks. The Cogle laboratory is a core laboratory for the NIH Cardiovascular Cell Therapy Research Network, testing the functional capacity of bone marrow and blood in patients who receive bone marrow injections in their hearts. In addition, new technologies are being developed to enhance the function of bone marrow cells to repair the injured hearts better.

Defining the Hemangioblast Activity of Leukemia Stem Cells
This project aims to define how leukemias exhibit hemangioblast activity, producing not only malignant leukemic cells but also malignant endothelial cells. The significance of this project is that if leukemia demonstrates hemangioblast activity, the generated malignant endothelia may serve as a sanctuary for later relapse. This begs for an alternative approach to leukemia treatment.

Clinical Interests:

Dr. Cogle’s clinical work focuses on the diagnosis and treatment of patients with the myelodysplastic syndromes (MDS), acute leukemias and bone marrow failure syndromes.  His clinical research has resulted in discovery of new biomarkers which identify patients who would best respond to specific treatments. In addition, he and his colleagues conduct clinical trials testing novel hypomethylating agents and antivascular therapies for patients with MDS and acute leukemias. Dr. Cogle also performs blood and marrow transplantation for patients with MDS, acute leukemias and bone marrow failure. He and his colleagues have developed new transplant regimens including purging techniques, haplotransplantation and mesenchymal stem cell infusion protocols. The overall objective of Dr. Cogle’s clinical and clinical research efforts is to better diagnosis and eradicate blood cancers.

Representative Publications:

• Cogle CR, Wainman DA, Jorgensen ML, Guthrie SM, Mames RN, Scott EW. Adult human hematopoietic cells provide functional hemangioblast activity. Blood, 103:133-135, 2004. PMID 12969964.
• Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, Scott EW. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet. 2004 May 1; 363(9419):1432-1437. PMID 15121406.
• Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, Lonergan J, Witold R, Krause DS, Scott EW. Bone marrow contributes to epithelial cancers in mice and humans as development mimicry. Stem Cells. 2007 Aug;25(8):1881-7. PMID 17478582.
• Cogle CR, Madlambayan GJ, Hubsher G, Speisman R, Beckman C, Tran-Son-Tay R, Pepine CJ. Marrow Cell Therapies for Cardiovascular Diseases. Experimental Hematology. 2008 Mar 27. PMID: 18375038

CV and NIH Biosketch:
http://www.cogle.com